DBV Technologies | DBVT - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amarin USD -2.26M 564K 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
DBV Technologies USD -34.28M 6.83M 2025-09
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Galectin Therapeutics USD -11.29M 1.64M 2024-06
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Incyte USD 324.17M 59.7M 2026-03
Insmed USD -200.28M 49.43M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
United Therapeutics USD 325.8M 340.4M 2026-03